Hikma Searches For Strategic ‘Fourth Leg’
Considering Deals For Specialty Or Biologic Injectables
To secure long-term growth, Hikma CEO Siggi Olafsson is seeking to add a fourth strategic pillar to its global generic Injectables, US non-injectable Generics and Middle East and North Africa Branded business segments.
